General Information about Pyrrolizidine Alkaloids (PAs)

PAs in Comfrey

Review of Comfrey and Related Research

• in vitro (Ames test, cell culture testing...)
• in vivo (Animal Studies)
• Topical Application
• Internal Use

Case Reports

Forum

Conclusions

References

Useful Links

About the Author

References

1. Stickel, F. and H.K. Seitz, The efficacy and safety of comfrey. Public Health Nutrition., 2000. 3(4A): p. 501-8.

2. Figueiredo, M.R. and M.A.C. Kaplan, Pyrrolizidine alkaloids: A word of caution. Ciencia e Cultura (Sao Paulo), 1997. 49(5-6): p. 331-338.

3. Stamford, I.F. and I.A. Tavares, The effect of an aqueous extract of comfrey on prostaglandin synthesis by rat isolated stomach. Journal of Pharmacy and Pharmacology, 1983. 35(12): p. 816-7.

4. Tunon, H., C. Olavsdotter, and L. Bohlin, Evaluation of anti-inflammatory activity of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis. Journal of Ethnopharmacology, 1995. 48(2): p. 61-76.

5. Lohmann, K., E. Reininger, and R. Bauer, Screening of European anti-inflammatory herbal drugs for inhibition of cyclooxygenase-1 and -2. Phytomedicine (Jena), 2000. 7(Supplement 2): p. 99.

6. Hiermann, A. and M. Writzel, Antiphlogistic glycopeptide from the roots of Symphytum officinale. Pharmaceutical and Pharmacological Letters, 1998. 8(4): p. 154-157.

7. Barthomeuf, C.M., et al., Evaluation of the dietetic and therapeutic potential of a high molecular weight hydroxycinnamate-derived polymer from Symphytum asperum Lepech. Regarding its antioxidant, antilipoperoxidant, antiinflammatory, and cytotoxic properties. J Agric Food Chem, 2001. 49(8): p. 3942-6.

8. Koll, R. and S. Klingenburg, [In Process Citation]. Fortschr Med Orig, 2002. 120(1): p. 1-9.

9. Goldman, R.S., P.C.D. De Freitas, and S. Oga, Wound healing and analgesic effect of crude extracts of Symphytum officinale in rats. Fitoterapia, 1986. 56(6): p. 323-330.

10. Kucera, M., J. Kalal, and Z. Polesna, Effects of Symphytum ointment on muscular symptoms and functional locomotor disturbances. Advances in Therapy, 2000. 17(4): p. 204-10.

11. Gafar, M., et al., [Apiphytotherapeutic original preparations in the treatment of chronic marginal parodontopathies. A clinical and microbiological study]. Revista de Chirurgie, Oncologie, Radiologie, O.R.L., Oftalmologie, Stomatologie. Seria: Stomatologie, 1989. 36(2): p. 91-8.

12. Taylor, A. and N.C. Taylor, Protective effect of Symphytum officinale on Mice bearing spontaneous and transport tumors. (28792). Proceedings of the Society of Experimental Biology and Medicine, 1963. 114: p. 772-774.

13. Summers, R.S., Cardiotoxic principle in comfrey [letter]. South African Medical Journal, 1979. 55(2): p. 37.

14. Gilani, A.H., et al., Pharmacological characterization of symphytoxide-A, a saponin from Symphytum officinale. Fitoterapia, 1994. 65(4): p. 333-339.

15. Lenghel, V., et al., The influence of some vegetable extracts on the in vitro adherence of mouse and human lymphocytes to nylon fibers. Roumanian Archives of Microbiology and Immunology, 1995. 54(1-2): p. 15-30.

16. Makhatadze, M., et al., Immunopharmacologic study of glucofructan from Symphytum asperum roots. Annals of the New York Academy of Sciences, 1993. 685: p. 383-5.

17. Van den Dungen, F., et al., High Molecular Weight Complement Inhibitors of Symphytum-Officinale. Clinical and Experimental Immunology, 1991. 86(SUPPL. 1): p. 3.

18. Stegelmeier, B.L., et al., Pyrrolizidine alkaloid plants, metabolism and toxicity. Journal of Natural Toxins, 1999. 8(1): p. 95-116.

19. Prakash, A.S., et al., Pyrrolizidine alkaloids in human diet. Mutation Research, 1999. 443(1-2): p. 53-67.

20. Mattocks, A.R., Chemistry and toxicology of pyrrolizidine alkaloids. 1986, London: Academic Press.

21. Mattocks, A.R., Toxicity of pyrrolizidine alkaloids. Nature, 1968. 217(130): p. 723-8.

22. Cheeke, P.R., Pyrrolizidine alkaloids, in Natural Toxicants in Feeds, Forages, and Poisonous Plants. 1998, Interstate Publishers: Danville, IL, USA. p. 338-352.

23. Culvenor, C.C., et al., Hepato- and pneumotoxicity of pyrrolizidine alkaloids and derivatives in relation to molecular structure. Chemico-Biological Interactions, 1976. 12(3-4): p. 299-324.

24. Cooper, R.A. and R.J. Huxtable, The relationship between reactivity of metabolites of pyrrolizidine alkaloids and extrahepatic toxicity. Proc West Pharmacol Soc, 1999. 42: p. 13-6.

25. Segall, H.J., et al., trans-4-Hydroxy-2-hexenal: a reactive metabolite from the macrocyclic pyrrolizidine alkaloid senecionine. Science, 1985. 229(4712): p. 472-5.

26. Schoental, R., Toxicology and carcinogenic action of pyrrolizidine alkaloids. Cancer Research, 1968. 28(11): p. 2237-46.

27. Weitz, H., et al., Veno-occlusive disease of the liver in patients receiving immunosuppressive therapy. Virchows Arch Pathol Anat, 1982. 395(3): p. 245-56.

28. Valla, D. and J.-P. Benhamou, Drug induced vascular and sinusoidal lesions of the liver. Bailliere's Clinical Gastroenterology, 1988. 2(2): p. 481-500.

29. Larrey, D., Hepatotoxicity of herbal remedies. Journal of Hepatology, 1997. 26(SUPPL. 1): p. 47-51.

30. Ito, N., et al., Veno-occlusive disease of the liver in a patient with allergic granulomatous angiitis. Am J Gastroenterol, 1988. 83(3): p. 316-9.

31. Etzioni, A., et al., Defective humoral and cellular immune functions associated with veno-occlusive disease of the liver. J Pediatr, 1987. 110(4): p. 549-54.

32. van Erpecum, K.J., et al., Generalized peliosis hepatis and cirrhosis after long-term use of oral contraceptives. Am J Gastroenterol, 1988. 83(5): p. 572-5.

33. Alpert, L.I., Veno-occlusive disease of the liver associated with oral contraceptives: case report and review of literature. Hum Pathol, 1976. 7(6): p. 709-18.

34. Russmann, S., et al., Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. European Journal of Gastroenterology and Hepatology, 2001. 13(3): p. 287-90.

35. Holtmann, M., et al., Veno-occlusive disease (VOD) in Crohn's disease (CD) treated with azathioprine. Dig Dis Sci, 2003. 48(8): p. 1503-5.

36. Bearman, S.I., Veno-occlusive disease of the liver. Current Opinion in Oncology, 2000. 12(2): p. 103-9.

37. Dobbie, M., et al., Veno-occlusive disease of the liver induced by gemcitabine [letter]. Annals of Oncology, 1998. 9(6): p. 681.

38. Ortega, J.A., et al., Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Childrens Cancer Group, the Pediatric Oncology Group, and the Pediatric Intergroup Statistical Center. Cancer, 1997. 79(12): p. 2435-9.

39. Winton, E.F. and P.A. McCue, High incidence of veno-occlusive disease related to indicine N-oxide in the treatment of refractory adult acute leukemia [letter]. Cancer Treatment Reports, 1986. 70(7): p. 933-4.

40. Huxtable, R.J., New aspects of the toxicology and pharmacology of pyrrolizidine alkaloids. General Pharmacology, 1979. 10(3): p. 159-67.

41. Pierson, M.L., P.R. Cheeke, and E.O. Dickinson, Resistance of the rabbit to dietary pyrrolizidine (Senecio) alkaloid. Res Commun Chem Pathol Pharmacol, 1977. 16(3): p. 561-4.

42. Hooper, P.T., Pyrrolizidine alkaloid poisoning - pathology with particular reference to difference in animal and plant species, in Effects of Poisonous Plants on Livestock, R.F. Keeler, K.R. VanKampen, and L.F. James, Editors. 1977, Academic Press: New York. p. 161-176.

43. Cheeke, P.R., Natural Toxicants in Feeds, Forages, and Poisonous Plants. Second ed. 1998, Danville, Illinois: Interstate Publishers, Inc. 479.

44. Schoental, R., Liver lesions in young rats suckled by mothers treated with the pyrrolizidine (senecio) alkaloids, lasiocarpine and retrorsine. Journal of Path. Bact., 1959. 77: p. 485-495.

45. Jago, M.V., A method for the assessment of the chronic hepatoxicity of pyrrolizidine alkaloids. Australian Journal of Experimental Biology and Medical Science, 1970. 48(1): p. 93-103.

46. Huxtable, R.J., Herbal teas and toxins: novel aspects of pyrrolizidine poisoning in the United States. Perspectives in Biology and Medicine, 1980. 24(1): p. 1-14.

47. Mattocks, A.R., The occurrence and analysis of pyrrolizidine alkaloid N-oxides. Xenobiotica, 1971. 1(4): p. 451-3.

48. Mattocks, A.R., Hepatotoxic effects due to pyrrolizidine alkaloid N-oxides. Xenobiotica, 1971. 1(4): p. 563-5.

49. Powis, G., M.M. Ames, and J.S. Kovach, Metabolic conversion of indicine N-oxide to indicine in rabbits and humans. Cancer Research, 1979. 39(9): p. 3564-70.

50. Brauchli, J., et al., Pyrrolizidine alkaloids from Symphytum officinale L. and their percutaneous absorption in rats. Experientia, 1982. 38(9): p. 1085-7.

51. Schoental, R. and P. Magee, Chronic liver changes in rats after a single dose of lasiocarpine, a pyrrolizidine (Senecio) alkaloid. Journal of Path. Bact., 1957. 74: p. 305-319.

52. Yan, C.C. and R.J. Huxtable, Effects of monocrotaline, a pyrrolizidine alkaloid, on glutathione metabolism in the rat. Biochemical Pharmacology, 1996. 51(3): p. 375-9.

53. Yan, C.C., R.A. Cooper, and R.J. Huxtable, The comparative metabolism of the four pyrrolizidine alkaloids, seneciphylline, retrorsine, monocrotaline, and trichodesmine in the isolated, perfused rat liver. Toxicology and Applied Pharmacology, 1995. 133(2): p. 277-84.

54. Yan, C.C. and R.J. Huxtable, Effects of taurine and guanidinoethane sulfonate on toxicity of the pyrrolizidine alkaloid monocrotaline. Biochemical Pharmacology, 1996. 51(3): p. 321-9.

55. Eisenstein, D., J. Azari, and R. Huxtable, Attenuation of the toxicity of a pyrrolizidine alkaloid (monocrotaline) by metabolic inhibition. Proceedings of the Western Pharmacology Society, 1979. 22: p. 193-8.

56. Petry, T.W. and I.G. Sipes, Modulation of monocrotaline-induced hepatic genotoxicity in rats. Carcinogenesis, 1987. 8(3): p. 415-9.

57. White, I.N., A.R. Mattocks, and W.H. Butler, The conversion of the pyrrolizidine alkaloid retrorsine to pyrrolic derivatives in vivo and in vitro and its acute toxicity to various animal species. Chemico-Biological Interactions, 1973. 6(4): p. 207-18.

58. Jago, M.V., Factors affecting the chronic hepatotoxicity of pyrrolizidine alkaloids. Journal of Pathology, 1971. 105(1): p. 1-11.

59. Kovach, J.S., et al., Toxicity and pharmacokinetics of a pyrrolizidine alkaloid, indicine N-oxide, in humans. Cancer Research, 1979. 39(11): p. 4540-4.

60. Muetterlein, R. and C.-G. Arnold, Investigations concerning the content and the pattern of pyrrolizidine alkaloids in Symphytum officalene L. (Comfrey). PZ (Pharmazeutische Zeitung) Wissenschaft, 1993. 138(5-6): p. 119-125.

61. Betz, J.M., et al., Determination of pyrrolizidine alkaloids in commercial comfrey products (Symphytum sp.). Journal of Pharmaceutical Sciences, 1994. 83(5): p. 649-53.

62. Chizzola, R., Rapid sample preparation technique for the determination of pyrrolizidine alkaloids in plant extracts. Journal of Chromatography A, 1994. 668(2): p. 427-433.

63. Copper, R.A., et al., Preparative separation of pyrrolizidine alkaloids by high-speed counter-current chromatography. Journal of Chromatography. a, 1996. 732(1): p. 43-50.

64. Couet, C.E., C. Crews, and A.B. Hanley, Analysis, separation, and bioassay of pyrrolizidine alkaloids from comfrey (Symphytum officinale). Natural Toxins, 1996. 4(4): p. 163-7.

65. Culvenor, C.C., et al., Structure and toxicity of the alkaloids of Russian comfrey (symphytum x uplandicum Nyman), a medicinal herb and item of human diet. Experientia, 1980. 36(4): p. 377-9.

66. Huxtable, R.J., J. Luthy, and U. Zweifel, [letter]. New England Journal of Medicine, 1986. 315(17): p. 1095.

67. Jaarsma, T.A., et al., Chemotaxonomy of the Symphytum officinale agg. (Boraginaceae). Plant Systematics and Evolution, 1989. 167(3-4): p. 113-128.

68. Mossoba, M.M., et al., Application of gas chromatography/matrix isolation/Fourier transform infrared spectroscopy to the identification of pyrrolizidine alkaloids from comfrey root (Symphytum officinale L.). Journal of AOAC International, 1994. 77(5): p. 1167-1174.

69. Awang, D.V., et al., Echimidine Content of Commercial Comfrey (Symphytum spp. Boranginaceae. Journal of Herbs, Spices, and Medininal Plants, 1993. 2(1): p. 21-35.

70. Furuya, T. and K. Araki, Studies on constituents of crude drugs. I. Alkaloids of Symphytum officinale Linn. Chemical and Pharmaceutical Bulletin, 1968. 16(12): p. 2512-6.

71. Kim, N.C., et al., Isolation of symlandine from the roots of common comfrey (Symphytum officinale) using countercurrent chromatography. Journal of Natural Products, 2001. 64(2): p. 251-3.

72. Roeder, E., T. Bourauel, and V. Neuberger, 73. Furmanowa, M., J. Guzewska, and B. Beldowska, Mutagenic effects of aqueous extracts of Symphytum officinale L. and of its alkaloidal fractions. Journal of Applied Toxicology, 1983. 3(3): p. 127-30.

74. Mattocks, A.R., Toxic pyrrolizidine alkaloids in comfrey [letter]. Lancet, 1980. 2(8204): p. 1136-7.

75. Roitman, J.N., Comfrey and liver damage [letter]. Lancet, 1981. 1(8226): p. 944.

76. Yeong, M.L., et al., The effects of comfrey derived pyrrolizidine alkaloids on rat liver. Pathology, 1991. 23(1): p. 35-8.

77. Ridker, P.M., et al., Hepatic venocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. Gastroenterology, 1985. 88(4): p. 1050-4.

78. Yamanaka, H., M. Nagao, and T. Sugimura, Mutagenicity of pyrrolizidine alkaloids in the Salmonella/Mammalian-Microsome Test. Mutation Research, 1979. 68: p. 211-216.

79. Reina, M., et al., Pyrrolizidine alkaloids from Heliotropium megalanthum. Journal of Natural Products, 1998. 61(11): p. 1418-20.

80. Wiedenfeld, H. and A. Andrade-Cetto, Pyrrolizidine alkaloids from Ageratum houstonianum Mill. Phytochemistry, 2001. 57(8): p. 1269-71.

81. Hirono, I., et al., Induction of hepatic tumors in rats by senkirkine and symphytine. Journal of the National Cancer Institute, 1979. 63(2): p. 469-72.

82. Hirono, I., et al., Edible plants containing carcinogenic pyrrolizidine alkaloids in Japan., in Naturally Occurring Carcinogens-Mutagens and Modulators of Carcinogenesis, E.C.e.a. Miller, Editor. 1979, Japan Science Society Press/Univeristy Park Press: Tokyo/Baltimore. p. 79-87.

83. White, R.D., et al., An evaluation of acetone extracts from six plants in the Ames mutagenicity test. Toxicology Letters, 1983. 15(1): p. 25-31.

84. Behninger, C., et al., [Studies on the effect of an alkaloid extract of Symphytum officinale on human lymphocyte cultures]. Planta Medica, 1989. 55(6): p. 518-22.

85. Bull, L.B., C.C. Culvenor, and A.T. Dick, The Pyrrolizidine Alkaloids. Frotiers of Biology, ed. A. Neuberger and E.L. Tatum. Vol. 9. 1968, Amsterdam: North-Holland Publishing Company.

86. Smith, L.W. and C.C. Culvenor, Plant source of Hepatotoxic pyrrolizidine alkaloids. Journal of Natural Products, 1981. 44(2): p. 129-152.

87. Hills, L.D., Comfrey. 1976, London: Faber and Faber Limited. 253.

88. Moore, M., Herbal Materia Medica. 4th ed. 1994, Albuquerque, NM: Southwest School of Botanical Medicine.

89. Hirono, I., H. Mori, and M. Haga, Carcinogenic activity of Symphytum officinale. Journal of the National Cancer Institute, 1978. 61(3): p. 865-9.

90. Garrett, B.J., et al., Consumption of poisonous plants (Senecio jacobaea, Symphytum officinale, Pteridium aquilinum, Hypericum perforatum) by rats: chronic toxicity, mineral metabolism, and hepatic drug-metabolizing enzymes. Toxicology Letters, 1982. 10(2-3): p. 183-8.

91. McDermott, W.V. and P.M. Ridker, The Budd-Chiari syndrome and hepatic veno-occlusive disease. Recognition and treatment. Archives of Surgery, 1990. 125(4): p. 525-7.

92. Weston, C.F., et al., Veno-occlusive disease of the liver secondary to ingestion of comfrey. British Medical Journal (Clinical Research Ed.), 1987. 295(6591): p. 183.

93. Senturk, T., et al., Seizures and hepatotoxicity following sulphasalazine administration. Rheumatology International, 1997. 17(2): p. 75-7.

94. Gran, J.T. and G. Myklebust, Toxicity of sulphasalazine in rheumatoid arthritis. Possible protective effect of rheumatoid factors and corticosteroids. Scandinavian Journal of Rheumatology, 1993. 22(5): p. 229-32.

95. Huang, J.L., et al., Successfully treated sulphasalazine-induced fulminant hepatic failure, thrombocytopenia and erythroid hypoplasia with intravenous immunoglobulin. Clinical Rheumatology, 1998. 17(4): p. 349-52.

96. Deltenre, P., et al., Mesalazine (5-aminosalicylic acid) induced chronic hepatitis. Gut, 1999. 44(6): p. 886-8.

97. Bach, N., S.N. Thung, and F. Schaffner, Comfrey herb tea-induced hepatic veno-occlusive disease [see comments]. American Journal of Medicine, 1989. 87(1): p. 97-9.

98. Yeong, M.L., et al., Hepatic veno-occlusive disease associated with comfrey ingestion. Journal of Gastroenterology and Hepatology, 1990. 5(2): p. 211-4.

99. Miskelly, F.G. and L.I. Goodyer, Hepatic and Pulmonary Complications of Herbal Medicines. Postgraduate Medical Journal, 1992. 68(805): p. 935.

100. Anderson, P. and A.E.M. McLean, Comfrey and Liver Damage. Human Toxicology, 1989. 8(1): p. 68-69.

101. Yeong, M.L., S.J. Wakefield, and H.C. Ford, Hepatocyte membrane injury and bleb formation following low dose comfrey toxicity in rats. International Journal of Experimental Pathology, 1993. 74(2): p. 211-7.

102. Grobner, M.A., P.R. Cheeke, and N.M. Patton, Effect if feeding comfrey on growth and tissue copper levels of rabbits. J applied rabbit research, 1985. 8(3): p. 136.

103. Cheeke, P.R., Comfrey: an excellent forage or a poisonous plant?. J applied rabbit research, 1979. 2(3): p. 7-11.

© 2004 Dorena Rode       Acknowledgment